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Abstract
Background: There is growing evidence that Bit1 exerts different roles in the development and progression of
human cancers. Although Bit1 was highly exhibited in ESCC tissues in our previous study, its roles and molecular
mechanisms implicated in development and progression of ESCC remain unknown.
Methods: Bit1 protein expression in ESCC cell lines and normal esophageal epithelial cell was detected by Western
blotting. Bit1 protein expression mediated by Bit1 shRNA was investigated by Western blotting. MTT, migration
assay, invasion experiment, ELISA and Flow cytometry were utilized to determine the effects of Bit1 knockdown on
cell proliferation, migration, invasion and apoptosis, respectively. A xenograft model was used to examine in vivo
tumourigenicity, and immunohistochemistry and TUNEL were utilized to evaluate the related protein expression
and apoptosis. Gene microarray was determined by Agilent SurePrint G3 Human GE 8 × 60 K Microarray, the
interaction of Bit1 and FAK proteins were detected by Immunoprecipitation and the key protein expressions of
FAK-paxillin pathway were detected by Western blotting.
Results: We found Bit1 expression in all human ESCC cell lines tested was significantly higher than that in normal
esophageal epithelial cell Het-1A (P < 0.05), in which EC9706 presented the highest Bit1 level. Bit1 protein level was
significantly downregulated at day 1 after transfection with specific shRNA against Bit1 (P < 0.05). At days 2 and 3,
Bit1 level reached the lowest value after transfection with Bit1 shRNA. Moreover, Bit1 depletion contributed to
growth inhibition in vitro and in vivo, reduced cell migration and invasion abilities, and induced cell apoptosis in
EC9706 and TE1 cells. More importantly, Bit1 downregulation significantly lowered Bcl-2 and MMP-2 levels in
EC9706 xenografted tumor tissues, meanwhile triggered apoptosis after treatment with different doses of Bit1
shRNA. Further gene microarray revealed that 23 genes in Bit1-RNAi group were markedly downregulated, whereas
16 genes were obviously upregulated. Notably, Bit1 intrinsically interacted with FAK protein in EC9706 cells.
Moreover, paxillin was downregulated at mRNA and protein levels in Bit1 shRNA group, coupled with the decreases
of FAK mRNA and protein expressions.
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Conclusion: Bit1 may be an important regulator in cell growth, apoptosis, migration and invasion of ESCC via
targeting FAK-paxillin pathway, and thereby combinative manipulation of Bit1 and FAK-paxillin pathway may be the
novel and promising therapeutic targets for the patients with ESCC.
Keywords: Bcl-2 inhibitor of transcription 1, FAK-paxillin pathway, esophageal squamous cell carcinoma, cell
migration, cell invasion
Background
Esophageal cancer is the one of the most frequently oc-
curring malignant neoplasms worldwide [1, 2], which
consists of two main subtypes, namely esophageal
adenocarcinoma (ECA) that is more common in the de-
veloped countries, such as North America and Europe
[3, 4], and esophageal squamous cell carcinoma (ESCC)
that is frequently occurring in the developing countries
[4–6], such as East Asian countries. At present, ESCC is
still the main histological subtype, accounting for more
than 90 % of cases of all esophageal cancers, with the
less than 10 % in 5-year survival rate of the patients with
ESCC [7–9]. Most importantly, about 50 % of the pa-
tients with ESCC exhibit the local invasion and metasta-
sis at the time of diagnosis, which will lead to the high
mortality [10, 11]. Despite recent advances in thera-
peutic strategies, a large number of patients with ESCC
remain poor clinical outcome. It is, therefore, dramatic-
ally necessary to seek and develop the novel molecular
target for therapy of the patients with ESCC.
Bcl-2 inhibitor of transcription 1 (Bit1) is a kind of mito-
chondria related protein, encoding 179 amino acid, which
is identified through Bcl-2 reporter system [12]. Evolution-
arily, Bit1 is verified to be dramatically conserved from
bacteria to humans [13]. Data from crystallographic stud-
ies have revealed in detail that human Bit1 harbors a
peptidyl-tRNA hydrolase domain, which is considered to
be implicated in protein translation and folding [14], and
thus Bit1 may harbors a large variety of functions involved
in the regulation of various biological processes.
In human cells, Bit1 can mediate integrin-dependent
survival signals via NF-κB signaling pathway [15], which
plays an essential role in the development and progres-
sion of many human cancers, suggesting Bit1 is tightly
associated with tumor development and progression. Al-
though few studies were reported regarding the connec-
tion between Bit1 and tumors, some data from ovarian
cancer demonstrated Bit1 overexpression was exhibited
in ovarian cancer tissues [16, 17], whereas other evi-
dence showed that Bit1 exerted tumor suppressor in
lung cancer [18]. These conflicting data about the differ-
ent roles of Bit1 in diverse human cancers will reinforce
us to further investigate its underlying biological roles in
the development and progression of ESCC. Our previous
studies revealed that Bit1 overexpression was exhibited
in ESCC tissues, and its overexpression was closely cor-
related with lymphatic metastasis, TNM staging and
tumor differentiation [19]. These data suggest that Bit1
plays different roles in various types of cancer, and
thereby elucidation of Bit1 function in different tumors
will provide a new diagnostic and therapeutic marker for
these tumors.
To further verify the underlying functions of Bit1 in
ESCC, therefore, in the present study, we examined Bit1
expression in a panel of ESCC cell lines, and investigated
the effects of Bit1 knockdown on tumor growth, migra-
tion and invasion as well as cell apoptosis in ESCC, and
further preliminarily elucidated the possible molecular
mechanisms. All data presented herein suggest Bit1 may
be a promising molecular target for the therapy of
ESCC, and thus intervention of Bit1 may lead to better
therapeutic outcomes for the patients with ESCC.
Results
Expression of Bit1 in a panel of ESCC cell lines
To dissect Bit1 protein level in ESCC, we detected Bit1
protein expression in a series of ESCC cell lines as well
as normal esophageal epithelial cell by Western blotting.
We found Bit1 protein expression was exhibited at high
level in all ESCC cell lines investigated in this study,
compared with that in Het-1A (Fig. 1a and b). However,
Bit1 level was differentially expressed in these ESCC cell
lines, and relative high level was displayed in EC9706,
Eca109, TE13 and KYSE-70 cells, the other ESCC cell
lines harbored lower Bit1 level, the difference was statis-
tical significance (P < 0.05) (Fig. 1a and b). Most notably,
expression of Bit1 protein in poorly differentiated KYSE-
70 cell line was significantly higher than that in well dif-
ferentiated KYSE-450, suggesting Bit1 may be positively
associated with malignant degree of ESCC. Therefore, to
further explore the possible roles of Bit1 in ESCC,
EC9706 with the highest Bit1 level was employed to in-
vestigate the functions of Bit1.
Specific shRNA against Bit1 reduces Bit1 protein level in
EC9706 and TE1 cells
To verify the duration time of Bit1 shRNA in EC9706
and TE1 cells, specific shRNA against Bit1 was used to
transfect to EC9706 and TE1 cells, and Bit1 protein ex-
pression was detected at days 1, 2, 3, 4, 5, 6, and 7 for
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EC9706 cells and at days 1, 2, 3 and 4 for TE1 cells by
Western blotting. The results demonstrated that com-
pared with EC9706 cells untreated and transfected with
negative shRNA, Bit1 protein level was significantly down-
regulated at day 1 after transfection with specific shRNA
against Bit1 (P < 0.05). At day 3, Bit1 level reached the
lowest value after transfection with Bit1-shRNA. Subse-
quently, with time progression, Bit1 protein level began to
gradually recover the control level, and Bit1 level at days 6
and 7 was similar with that of control group (P > 0.05)
(Fig. 2a and b). Furthermore, compared with TE1 cells un-
treated and transfected with negative shRNA, Bit1 protein
level was significantly reduced on days 1, 2, 3 and 4, and
at day 3, Bit1 level reached the lowest value after transfec-
tion with Bit1-shRNA (Fig. 2c and d). These findings sug-
gest that the optimum time of Bit1 shRNA appears at day
3 in both EC9706 and TE1 cells.
Bit1 knockdown suppresses cell proliferation, migration
and invasion in EC9706 and TE1 cells
To test whether Bit1 depletion affected cell proliferation,
migration and invasion abilities, MTT, Wound healing
migration assay and Transwell invasion experiment were
utilized to determine the effects of Bit1 knockdown on
cell proliferation, migration and invasion abilities, re-
spectively. We found that cell proliferation was signifi-
cantly suppressed on days 2, 3, 4 and 5 after transfection
with Bit1-shRNA in EC9706 cells, compared with un-
treated group and negative group (P < 0.05) (Fig. 3a),
which was almost consistent with the data from Bit1
shRNA mediated the alteration of Bit1 protein expres-
sion at different time points. However, regarding TE1
cells, Bit1 downregulation also significantly suppressed
cell proliferation on days 6 and 7 compared with un-
treated group and negative group (P < 0.05) (Fig. 3b).
Stepwise investigation from Wound healing migration
assay revealed that migration distance of EC9706 and
TE1 cells in Bit1 shRNA group at different time points
(12 h, 24 h and 36 h) was all significantly lower than
those in untreated group and negative group (P < 0.05)
(Fig. 3c, d, e and f), suggesting Bit1 shRNA can inhibit
cell migration in both EC9706 and TE1 cells. Further-
more, the results from Transwell invasion experiment
demonstrated that invasive cell numbers of EC9706 and
TE1 cells in Bit1 shRNA group were markedly lower
than those in untreated group and negative group (P <
0.05) (Fig. 3g, h and i). These findings suggest that Bit1
may exert essential roles in the regulation of cell growth,
migration and invasion abilities in ESCC.
Knockdown of Bit1 expression promotes EC9706 and TE1
cell apoptosis
To further confirm the role of Bit1 as an anti-apoptosis
factor in ESCC cells, we examined whether knockdown
of endogenous Bit1 expression will impact the apoptosis
of EC9706 and TE1 cells. We reasoned that EC9706
and TE1 cells underwent apoptosis if ablation of the Bit1
anti-apoptotic pathway may trigger cell apoptosis. In-
deed, following a protracted 72 h culture after transfec-
tion with pSilencer3.1-H1-neo-Bit1-shRNA, the EC9706
cells eventually showed obvious apoptosis, but there was
no statistical difference (P > 0.05) among different groups
(Bit1 shRNA, Negative and Untreated groups) that sam-
ple size was calculated according to the previous results
using the following equation: N1 ¼ N2 ¼ 2 Za=2þZβð Þσδ
 2
.
Where with significance level α = 0.05 and power 1-β = 0.8,
we found that the study would therefore need sample size
N1 =N2 = 10 for the Independent-Samples T test. As com-
pared to the EC9706 parental or negative-shRNA treated
cells, the Bit1-shRNA transfected cells exhibited increased
apoptosis at 72 h (Fig. 4a), and similar results were found in
TE1 cells when the sample size N1 =N2 = 15 (Fig. 4b). Fur-
thermore, the results of Flow cytometry demonstrated that
the early apoptotic cell numbers and total apoptotic cell
Fig. 1 Bit1 protein expression in many different ESCC cell lines and
normal esophageal epithelial cell Het-1A. Total protein was extracted
from various ESCC cell lines such as EC9706, Eca109, TE1, TE13, KYSE-450
and KYSE-70 as well as Het-1A, and Western blotting was utilized to
investigate the Bit1 protein level in ESCC cell lines above. a Western
blotting assay for Bit1 protein expression in ESCC cell lines including
EC9706, Eca109, TE1, TE13, KYSE-450 and KYSE-70 as well as Het-1A, and
β-actin was used as internal control. b The relative Bit1 protein level was
counted by the ratio of Bit1 level to β-actin level, and the results from
the three independently repeated experiments, expressed as means ±
SD, were investigated by SPSS 17.0 statistical software, *P< 0.05,
compared with EC9706, Eca109, TE13, and KYSE-70, #P< 0.01, compared
with the other ESCC cell lines, **P< 0.01, compared with all of ESCC
cell lines
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numbers of EC9706 and TE1 cells in Bit1 shRNA group
were both markedly increased compared with untreated
group and negative group (P < 0.05) (Fig. 4c, d and e).
Bit1 downregulation reduced tumorigenicity in EC9706
xenografted nude mice
Based on cell proliferation inhibition in vitro mediated
by Bit1 knockdown, we proposed whether decrease of
Bit1 level suppressed tumorigenicity in EC9706 xeno-
grafted nude mice. In the current study, two doses of
pSilencer3.1-H1-neo-Bit1-shRNA or pSilencer3.1-H1-
neo-negative-shRNA (5 μg and 10 μg) were employed to
treat the tumors in EC9706 xenografted nude mice
model. We found that compared with negative group,
10 μg of pSilencer3.1-H1-neo-Bit1-shRNA significantly
suppressed tumor growth (P < 0.05) (Fig. 5a and b), but
5 μg of pSilencer3.1-H1-neo-Bit1-shRNA didn’t inhibit
tumor growth (P > 0.05) (Fig. 5a and b), suggesting Bit1-
shRNA mediated inhibitory effect on tumor growth dis-
plays in a dose-dependent manner.
Bit1-shRNA reduced the levels of Bit1, Bcl-2 and MMP-2
as well as induced cell apoptosis in EC9706 xenografted
nude mice
To further delineate the expressions of Bcl-2 and MMP-
2 proteins closely related to Bit1, the sacrificed nude
mice tumor tissues were carefully analyzed by qRT-PCR,
Immunohistochemistry and In Situ Apoptosis Detection
assays as described above. The results revealed that Bit1,
Bcl-2 and MMP-2 mRNA level in xenografts tissues of
5 μg-shRNA treated group was significantly lower than
those in 5 μg-negative treated group (P < 0.05), similarly,
the mRNA levels of the three genes in 10 μg-shRNA
treated group were also markedly less than those in
10 μg-negative treated group (P < 0.01) (Fig. 6a). In
addition, the IOD values of Immunohistochemistry re-
lated expressions of Bit1, Bcl-2 and MMP-2 proteins
were in line with the results of qRT-PCR. Briefly, expres-
sions of Bit1, Bcl-2 and MMP-2 proteins in 5 μg-shRNA
group (58.44 ± 4.17, 68.89 ± 9.43 and 80.94 ± 5.76) were
obviously lower than those in 5 μg-negative group
(87.57 ± 2.51, 111.83 ± 10.08 and 120.64 ± 8.29), similarly,
their expressions in 10 μg shRNA-group (54.47 ± 5.27,
56.62 ± 4.50 and 65.50 ± 5.33) were also remarkably re-
duced compared with 10 μg-negative group (92.97 ±
4.72, 110.91 ± 3.59 and 119.84 ± 4.94) (Fig. 6b and c). Be-
sides, in 5 μg-shRNA, 5 μg-negative, 10 μg-shRNA and
10 μg-negative groups, the numbers of apoptotic cells
were 45/1000, 157/1000, 55/1000 and 231/1000, respect-
ively, and the differences were statistical significance (P
< 0.05) (Fig. 6d and e). These data presented herein sug-
gest that Bit1 downregulation may be tightly associated
Fig. 2 Bit1 shRNA efficiently reduced Bit1 protein level in EC9706 and TE1 cells. Total protein was extracted from EC9706 and TE1 cells untreated
and transfected with Bit1 shRNA and negative shRNA at different time points, and Western blotting was used to investigate the Bit1 protein level.
a Western blotting assay for Bit1 protein level in untreated group, negative group and Bit1 shRNA group at different time points including days 1,
2, 3, 4, 5, 6 and 7 in EC9706 cells. b The relative Bit1 protein level was counted by the ratio of Bit1 level to β-actin level in EC9706 cells, and the
results from the three independently repeated experiments, expressed as means ± SD, were investigated by SPSS 17.0 statistical software, *P < 0.05,
compared with untreated EC9706 cells, negative group, EC9706 cells on days 6 and 7 after transfection with Bit1 shRNA, **P < 0.05, compared with the
other groups, # P < 0.05, compared with EC9706 cells on day 5. c Western blotting assay for Bit1 protein level in untreated group, negative group and
Bit1 shRNA group at different time points including days 1, 2, 3 and 4 in TE1 cells. d The relative Bit1 protein level was counted by the ratio of Bit1 level
to β-actin level in TE1 cells, and the results from the three independently repeated experiments, expressed as means ± SD, were investigated by SPSS
17.0 statistical software, *P < 0.05, compared with untreated EC9706 cells and negative group, **P < 0.05, compared with the other groups
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with the reduces of Bcl-2 and MMP-2 protein levels,
and thus results in the alterations of cell apoptosis, mi-
gration and invasion of EC9706 cells.
Bit1 downregulation altered gene expression profiles in
EC9706 cells
To further dissect the possible molecular mechanisms me-
diated by Bit1 downregulation, microarray was utilized to
identify differently expressed genes in Bit1 shRNA group
and negative group. According to method of multiplicity,
143 differently expressed genes were screened out in Bit1
shRNA group and negative control group in EC9706 cells,
in which 79 genes were upregulated and 64 genes were
downregulated (P < 0.05). 143 differently expressed genes
were submitted to DAVID website, and 113 genes were rec-
ognized by DAVID database. In addition, functional
Fig. 3 The effects of Bit1 depletion on cell proliferation, migration and invasion abilities in ESCC EC9706 and TE1 cells. a and b Bit1-shRNA
significantly suppressed cell growth on days 2, 3 and 4 in EC9706 and TE1 cells. EC9706 and TE1 cells at a density of 5,000 cells per well were seeded
into 96-well culture plates. When cells were cultured for 24 h, and the pSilencer3.1-H1-neo-Bit1-shRNA and pSilencer3.1-H1-neo-negative-shRNA
were utilized to transfect EC9706 and TE1 cells. The number of metabolically active cells was assessed by 3- (4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) assay at each indicated time (1d, 2d, 3d, 4d, 5d, 6d and 7d). c and e Bit1 knockdown markedly impeded
cell migration in EC9706 and TE1 cells. 4 × 105 of EC9706 and TE1 cells were seeded into 6-well culture plates. After transfection with
pSilencer3.1-H1-neo-Bit1-shRNA and pSilencer3.1-H1-neo-negative-shRNA for 24 h, in vitro scratch wounds were created by scraping the cell
monolayers with a 200 μl sterile pipette tip. The wounded cultures were allowed to grow for 36 h at 37 °C. At 12 h, 24 h and 36 h, photomicrographs
were taken at the same position to evaluate the alterations of cell migration ability. d and f Cell migration was assessed by measuring migration
distances from the wound edges. *P < 0.05, compared with untreated and negative group. g Bit1 downregulation contributed to the decrease of cell
invasion ability in EC9706 and TE1 cells. After transfection with pSilencer3.1-H1-neo-Bit1-shRNA and pSilencer3.1-H1-neo-negative-shRNA for 24 h,
EC9706 and TE1 cells (3-5 × 104 per well) were seeded to ECM gel pre-coated, porous upper chamber inserts and allowed to grow at 37 °C in a CO2
incubator. The cells that invaded to the bottom surface of the insert were fixed with methanol and stained by 0.5 % crystal violet, and was then subjected
to microscopic inspection. h and i The invasive cell numbers were counted to evaluate the effect of Bit1-shRNA on cell invasion ability in EC9706 and TE1
cells, **P< 0.01, compared with untreated and negative groups
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annotation using the Gene Ontology (GO) terms demon-
strated that 24 genes was appeared in GO function anno-
tation clusters, and its functional type was implicated in
cell adhesion, extracellular matrix joint and biological
adhesion, ect. These genes were tightly associated with
several signaling pathways, including Notch signaling
pathway,NOD-like receptor signaling pathway,MAPK
signaling pathway, Focal adhesion,PI3K-Akt signaling
pathway, etc. In functional classification and signaling
pathways above, 16 upregulated genes (AKAP9, ARH-
GEF4, RUNX1, FGF18, PARVB, PRDX4, RPS6KA2,
ADORA2A, IL1R1, CRP, WNT, IL-2RA, IFN, ARAP1,
IFNA6 and VLDLR) and 23 downregulated genes
(CMKLR1, SLA2, HNF1A, PPP1R1C, ZNF423, FAM19A4,
TLE1, NLRP3, PAXILLIN, BAX, CBLB, MLLT4, ERBB3,
MEF2C, ATF2, TALIN, PDGFRA, TIAM1, CAMK4,
EIF4E1B, ERCC5, TLR7 and IL-6) were selected for
future investigation (Fig. 7). These findings suggest that
Bit1 may be involved in multiple different molecular
mechanisms in ESCC.
Bit1 interacted with FAK protein as well as Bit1
downregulation evoked the decrease of FAK and Paxillin
expressions in EC9706 cells
Study demonstrated that Bit1 and FAK were in a complex
in adherent cells [15], we put forward whether Bit1 could
interact with FAK in EC9706 cells. We found that on both
substrates, FAK were detected in Bit1 immunoprecipita-
tions, meanwhile, Bit1 was detected in FAK immunopre-
cipitations (Fig. 8a) It is well documented that FAK and
Paxillin is tightly associated with tumor progression, mi-
gration, invasion and metastasis in many tumors [20–24].
Therefore, to further verify the validation of gene chip,
real-time qPCR and Western blotting was utilized to de-
tect the expressions of paxillin and FAK in Bit1 shRNA
group. We found that Bit1 shRNA significantly donwregu-
lated paxillin mRNA and protein expressions, compared
with untreated group and negative group (P < 0.05)
(Fig. 8b, c and d), which was consistent with gene chip re-
sults, coupled with reduced FAK expression (P < 0.05)
(Fig. 8b, c and d). These findings suggest that Bit1
Fig. 4 Knockdown of Bit1 expression promotes EC9706 and TE1 cell apoptosis. After transfected with pSilencer3.1-H1-neo-Bit1-shRNA or
pSilencer3.1-H1-neo-negative-shRNA for 72 h, cells were subjected to Cell Death ELISA. Three independent experiments were performed. a ELISA
assay for cell apoptosis in EC9706 cells; b ELISA assay for cell apoptosis in TE1 cells; c Flow cytometry assay for cell apoptosis in EC9706 and TE1
cells; d Three independently repeated experiment for cell apoptosis in EC9706 cells; e Three independently repeated experiment for cell
apoptosis in TE1 cells; *P < 0.05 as compared to untreated and negative groups
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downregulation mediated reduced invasion ability may be
achieved via FAK-paxillin signaling pathway.
Discussion
Increasing evidence has demonstrated that mitochon-
dria dysfunction leads to many diseases [25–28], such
as Alzheimer, Parkinson, tumor, etc., which is tightly
associated with aberrant alterations of gene expression
profiles. Bit1, as a mitochondria protein, also was veri-
fied to be implicated in tumor development and
progression in many documented publications [18, 29–31].
Our previous studies demonstrated that Bit1 expression
was significantly higher than that in normal esophageal
tissues [19], which was further supported by our current
study in a panel of ESCC cell lines. Interestingly, Bit1 ex-
pression in poorly-differentiated ESCC cell lines was
higher than that in well-differentiated ESCC cell lines,
suggesting Bit1 may function as oncogene in ESCC. Over-
all, these findings suggest that Bit1 may play an essential
role in the development and progression of ESCC.
Fig. 5 Bit1 shRNA significantly suppressed tumor growth in EC9706 xenografted nude mice. Bit1 shRNA mediated the inhibitory effect on tumor
growth in EC9706 xenografted nude mice. EC9706 cells (4 × 106 per nude mouse) were inoculated into the back of right flank of each nude
mouse. When tumor volume reached approximately 100 mm3 (about on day 5), nude mice were randomly split into four groups: 1: negative
(5 μg), 2: negative (10 μg), 3: shRNA (5 μg) and 4: shRNA (10 μg), and treatment and tumor volume measurement were performed every 4 days.
The mice in different groups were injected via intratumor route with the different complexes, which consists of pSilencer3.1-H1-neo-Bit1-shRNA
(5 μg and 10 μg) or pSilencer3.1-H1-neo-negative-shRNA (5 μg and 10 μg) and corresponding volume of Lipofectamine 2000. When
measurement was terminated, the animals were sacrificed on day 21, and tumor tissues were collected. Finally, tumor growth curve was made to
evaluate the effect of Bit1-shRNA on tumor growth. a Sacrificed animals and corresponding tumors in different groups. b Tumor growth curve in
different groups. *P < 0.05, compared with negative groups and shRNA group (5 μg)
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It is well documented that balance between tumor onco-
gene and suppressor play predominant roles in the devel-
opment and progression of a variety of human tumors.
Bit1, as an oncogene or a tumor suppressor, seems to be
in a context-dependent manner through many different
molecular mechanisms. Yao X et al. found that reintro-
duction of Bit1 was sufficient to suppress the anchorage-
independent growth; conversely, Bit1 downregulation sig-
nificantly enhances anchorage-independent growth in
A549 cells and further investigation revealed that the
Bit1-depletion cells displayed significantly enhanced
tumorigenecity in vivo [18], implying Bit1 functions as
tumor suppressor in lung carcinoma. Conversely, Bit1 de-
pletion contributed to cell growth suppression in cervical
cancer cell line HeLa, compared with control cells [15].
To test whether Bit1 downregulation affected cell
growth in ESCC, MTT assay and nude mice xenografts
were utilized to investigate the effects of Bit1 knock-
down on cell growth in ESCC, we found that Bit1 down-
regulation markedly suppressed cell growth in vitro
and in vivo, implying Bit1 functions tumor suppressor
in ESCC.
Fig. 6 Bit1-shRNA triggered the decreases of Bit1, Bcl-2 and MMP-2 expressions as well as cell apoptosis in xenografted nude mice. When the
measurement of tumor volume was terminated, tumor tissues were harvested, and real-time qPCR and Western blotting were utilized to detect
the expressions of Bit1, Bcl-2 and MMP-2 mRNAs and proteins. a Real-time qPCR investigation for expressions of Bit1, Bcl-2 and MMP-2 mRNAs in
different doses Bit1 shRNA or negative shRNA groups. b Immunohistochemistry assay for expressions of Bit1, Bcl-2 and MMP-2 proteins in different
doses Bit1 shRNA or negative shRNA groups. c Average density assay of Bit1, Bcl-2 and MMP-2 protein levels in different doses Bit1 shRNA or negative
shRNA groups. d TUNEL assay for cell apoptosis in different doses Bit1 shRNA or negative shRNA groups. e Apoptotic index was counted according to
apoptotic cell number under 5 randomly selected fields. *P < 0.05, compared with 5 μg negative group, **P < 0.01, compared with 10 μg
negative group
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Invasion and metastasis are one of the typical hall-
marks of tumors. The investigation from Karmali PP
and colleagues demonstrated that metastatic numbers
and foci in Bit1-depletion B16F1 cells were significantly
increased compared with control B16F1 cells, whereas
Bit1 overexpression by exogenous introduction reduced
the formation of lung metastatic colonies [32], implying
Bit1 functions as the suppressor of metastasis in melan-
oma. Contrary to this result, in the current study, we
found Bit1 downregulation contributed to the decreases
of migration and invasion abilities of ESCC EC9706 and
TE1 cells. These findings suggest that the role exerted
by Bit1 in invasion and metastasis may be associated
with tumor types, however, its precise molecular mecha-
nisms involved in invasion and metastasis of ESCC re-
mains to be elucidated in future.
In previous study, Bit1 was verified to be a critical
apoptosis regulator through manipulation of Bcl-2
expression [12]. Several studies have demonstrated that
Bcl-2 is tightly associated with tumor development and
progression [33–35], and thus may be an underlying
molecular biomarker. It is well documented that
MMP-2 is implicated in tumor invasion and metasta-
sis, which is also confirmed in some publications
[36–38]. Therefore, to further confirm the role of
Bit1 in EC9706 cells xenografted nude mice, we found
that Bit1 downregulation mediated by shRNA signifi-
cantly decreased the levels of Bcl-2 and MMP-2
mRNA and proteins in EC9706 cells xenografted nude
mice, compared to negative groups, coupled with the
increases of apoptotic index. These data indicate that
the alterations of cell growth, migration and invasion
triggered by Bit1 depletion is tightly involved in the
regulation of Bcl-2 and MMP-2, however, precise mo-
lecular mechanisms related to these changes above is
under investigation.
Fig. 7 Gene chip assay for differently expressed genes in EC9706 cells treatment with Bit1 shRNA or negative shRNA. EC9706 cells were
transfected with Bit1-shRNA or negative shRNA, and cells were subjected to gene chip assay. Data were annotated using the SAS Analysis System
and filtered by signal intensity and detection call. Gene expression fold changes were compared between Bit1-shRNA treated and negative-shRNA
treated cells. *P < 0.05, differently expressed genes between two groups were considered as statistical significance
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Understanding the molecular mechanisms of Bit1 in-
volved in development and progression of tumors is crucial
and helps to accelerate the development of drugs that target
Bit1 or its related signaling pathways. To further clarify the
signaling pathway mediated by Bit1 downregulation, we
performed array assay by gene chip, we found that Bit1
downregulation triggered 23 genes downregulation and 16
genes upregulation in EC9706 cells, which was implicated
in cell apoptosis, cell adhesion, invasion and metastasis,
etc., suggesting Bit1 may be an important regulator in cell
invasion and metastasis of ESCC. Currently, increasing evi-
dence has demonstrated that paxillin is highly expressed in
many tumors, and is tightly associated with development,
progression, invasion, metastasis and poor prognosis of a
multiple of human tumors [39–45]. Furthermore, FAK-
paxillin signaling pathway participates in the processes of
tumor invasion and metastasis via different molecular
mechanisms in many human tumors [46–48], and thus
may be a potential predictor for metastasis of tumors. To
establish the connections of Bit1 and FAK-paxillin signaling
pathway, immunoprecipitation was employed to verify the
interaction of Bit1 and FAK proteins in EC9706 cells. We
found Bit1 intrinsically interacted with FAK protein in
EC9706 cells. To further understand the underlying mecha-
nisms of Bit1 downregualtion mediated the alterations of
migration and invasion, and verify the validation of paxillin
expression obtained by gene chip in EC9706 cells, we de-
tected the expressions of paxillin and its related protein
FAK by Real-time qPCR and Western blotting. The results
revealed that paxilllin and FAK expressions were markedly
decreased, compared with untreated group and negative
control group, implying Bit1 functions as invasion and me-
tastasis- regulator through FAK-paxillin signaling pathway,
however, precise molecular mechanisms mediated by Bit1
downregulation remain under investigation. Based on the
results above, we put forward to a novel pathway Bit1-FAK-
paxillin, which participates in the invasion and metastasis
of ESCC, and manipulation of the signaling pathway may
be a potentially molecular target in future.
Conclusion
Collectively, our data suggest that Bit1 expression is exhib-
ited at the high level in ESCC cell lines, and its expression
in poorly-differentiated ESCC cell lines is significantly
higher than that in well-differentiated ESCC cell lines. Bit1
downregulation significantly suppresses cell growth in vitro
and in vivo, and reduces the migration and invasion abilities
in ESCC cells, which may be tightly associated with de-
creases of Bcl-2 and MMP-2 expressions. Combined with
gene chip results, stepwise investigation indicates that Bit1
intrinsically interacted with FAK protein in EC9706 cells,
and Bit1 downregulation significantly reduces paxillin and
FAK expression. Future directions will be to develop the
Bit1 as novel molecular target for the patients with ESCC,
which may be implicated in large numbers of molecular
regulation mechanisms of Bit1 in ESCC.
Methods
Cell lines and culture conditions
The human ESCC cell lines EC9706, Eca109, TE1, TE13,
KYES-450 and KYSE-70 were all purchased from the
Tumor Cell Bank of Chinese Academy of Sciences, and
both maintained in Roswell Park Memorial Institute
(RPMI) 1640 media supplemented with 10 % Fetal bovine
serum (FBS), 1 % L-Glutamine and 1 % Penicillin-
Streptomycin (Solarbio Life Technologies, Beijing, China).
Normal esophageal epithelial cell Het-1A immortalized by
introducing plasmid pRSV-T with RSV-LTR promoter and
SV40 T antigen [49] was purchased from the American
Type Culture Collection (Manassas, VA, USA), which was
also maintained under the culture conditions above. All of
the cells were cultured at 37 °C under 5 % humidified CO2
enriched atmosphere.
Protein extraction and Western blotting
Cells were washed twice with ice-cold PBS, and col-
lected cells were lysed in buffer (Beyotime Institute of
Biotechnology, Shanghai, China). Protein concentration
was determined using Bradford reagent (Sigma-Aldrich,
San Luis, MO, USA) according to standard precedures.
Total protein (0.4 mg) was added to 5× protein sample
buffer, heated at 100 °C for 2 min and separated by SDS-
PAGE with 3 μl of pre-stained protein molecular weight
marker (Fermentas Life Sciences, Burlington, ON,
Canada) as a standard, which was transferred to a poly-
vinylidene fluoride (PVDF) membrane and incubated
with the following respective primary antibodies includ-
ing anti-Bit1 (1:10000), anti-FAK (1: 1000), anti-paxillin
(1:200), and control anti-β-actin (1:500) overnight at 4 °
C, followed by secondary antibodies (goat anti mouse,
1:5000, goat anti rabbit, 1:2000) conjugated with horse-
radish peroxidase. Membranes were developed using
the ECL detection system (Beyotime Institute of Bio-
technology, Shanghai, China). Quantification of West-
ern blotting was performed using Quantity-One
software (NIH) to determine the relative protein level,
and the results were from at least three independently
repeated experiments.
Quantitative real-time RT-PCR
Quantitative real-time RT-PCR (real-time qPCR) assay
was performed as our previous report [19]. Briefly, total
RNA was extracted from 100 mg of the mice tumors or
cells by using TRIzol reagent (Invitrogen, USA). The
cDNA was prepared using a reverse transcription re-
agent kit (TaKaRa Company, Dalian, China) according
to the manufacturer's instructions. Target genes were
amplified using ABI 7500 Real-Time PCR System (USA)
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with the following specific primers: Bit1, 5’-AGAGG
TAGCTCACGCGATAGAA-3’ (forward) and 5’-GCATC
CCAAAGCATA CTCGAA-3’ (reverse) (product length,
196 bp); Bcl-2, 5′-CAGCTGCACCTGACGCC CTT-3’
(forward) and 5’-GCCTCCGTTATCCTGGATCC-3’ (re-
verse) (product length, 230 bp); MMP-2, 5’-CTCCTGAC
ATTGACCTTGGC -3’ (forward) and 5’-CCTCGCT CC
AGGGTGCTGGC-3’ (reverse) (product length, 310 bp);
FAK, 5’-AGTAAAATCC AGCCAGCCCC-3’ (forward) and
5’-GACATACTGCTGGGCCAGTT-3’ (reverse) (product
length, 207 bp); paxillin, 5’-CTGTCGGATTTCAAGTTC
ATGGC-3’ (forward) and 5’-TGGGTGCAGACGAAG T
GC-3’(reverse) (product length, 239 bp) as well as GAPDH,
5’-GCACCGTCAAGGCTGAGAAC-3’ (forward) and
5’-TGGTGAA GACG CCAGTGGA-3’ (reverse) (product
length, 138 bp); GAPDH was utilized as normalization.
Each sample was tested in triplicate, and the gene relative
levels were normalized using the 2−ΔΔCt method according
to a previous description [50].
Liposome mediated cell transfection assay
EC9706 and TE1 cells were seeded in a 6-well plate at a
density of 4 × 105 for 24 h before transfection. The pSilen-
cer3.1-H1-neo-negative-shRNA and pSilencer3.1-H1-neo-
Bit1 -shRNA plasmids were generated as described
previously [31]. Experiments were divided into three
groups: untreated group (transfection with Lipofectamine
2000), negative group (transfection with pSilencer3.1-H1-
neo-negative-shRNA), and Bit1 shRNA group (transfection
with pSilencer3.1-H1-neo-Bit1-shRNA). Transfection was
carried out according to the manufacturer’s instructions
using pSilencer3.1-H1-neo-Bit1-shRNA or pSilencer3.1-
H1-neo-negative-shRNA plasmids at final quantifications
of 2-4 μg, and untreated group was transfected with Lipo-
fectamine 2000 reagent (Invitrogen, USA) alone as control.
Cells were harvested and subjected to immunoblotting, mi-
gration, transwell, ELISA, or Microarray assays as described
below 72 h after transfection.
Cell proliferation
For proliferation assay, cells were plated in a volume of
150 μl at a density of 5,000 cells per well in 96-well plates,
which was allowed grow for 24 h and then transfected with
the pSilencer3.1-H1-neo-Bit1-shRNAor pSilencer3.1-H1-
neo-negative-shRNA. At each indicated time point (1d, 2d,
3d, 4d, 5d, 6d and 7d for EC9706 cells and 1d, 2d, 3d and
4d for TE1 cells), the numbers of metabolically active
cells were assessed by 3- (4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) assay. Briefly, MTT
reagent (Sigma, USA) was dissolved in sterile PBS at
Fig. 8 Bit1 interacted with FAK protein as well as Bit1 downregulation contributed to the suppression of FAK-paxillin signaling pathway. a Bit1
forms a complex with FAK protein in either Bit1 or FAK immunoprecipitation (IP). b Real-time qPCR investigation for the relative levels of paxillin
and FAK mRNAs in different treatment EC9706 cells, and GAPDH was utilized as internal control, the relative levels of paxillin and FAK mRNAs
were counted according to 2-△△Ct. c Western blotting assay for the expressions of paxillin and FAK proteins in different treatment EC9706 cells,
and β-actin was utilized as internal control. d Relative levels of paxillin and FAK proteins were counted according to the ratio of interest protein
to β-actin. *P < 0.05, compared with untreated group and negative group
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5 mg/ml. 20 μl of this solution was added to each well in a
96-well plate (1:5 dilution). The plate was then incubated
for 4 h at 37 °C in 5 % humidified CO2 enriched atmosphere.
Afterwards, the medium was gently aspirated away and the
MTT precipitate was dissolved in 100 μl of a 50 % MeOH-
50 % DMSO solution. The precipitate was allowed to dis-
solve at room temperature for 10 min with gentle shaking.
Absorbance (A) was measured at a wavelength of 490 nm
using a Microplate Reader (BIO-TEK, Winooski, USA).
Cell migration experiment
Migration of ESCC EC9706 and TE1 cells was investigated
by Wound healing migration assay. Viable cells were
plated at 4 × 105 cells per well in 6-well culture plates
using growth media containing 10 % FBS. After transfec-
tion with pSilencer3.1-H1-neo-Bit1-shRNA and pSilen-
cer3.1-H1-neo–negative-shRNA vectors for 24 h, in vitro
scratch wounds were created by scraping the cell mono-
layers with a 200 μl sterile pipette tip. After washing away
suspended cells, photomicrograph was taken immediately
(time 0 h) with an inverted microscope equipped with a
digital camera, and the wounded cultures were allowed to
grow for 36 h at 37 °C. At 12 h, 24 h, 36 h, photomicro-
graphs were taken at the same position, respectively.
Migrations at least three independently repeated experi-
ments were quantified by measuring distances from the
wound edges.
Cell invasion assay
To determine whether the invasion ability of ESCC
EC9706 and TE1 cells was mediated by Bit1 shRNA.
Transwell invasion assay was performed as Corning’s
Transwell chambers (24-well plate, 6.5 mm in diameter
with 8.0 μm pores) with 100 μl of Matrigel basement
membrane matrix (BD Bioscience, Bedford, MA) per
well and solidified at 37 °C for 30 min. Briefly, after
transfection with pSilencer3.1-H1-neo-Bit1-shRNA or
pSilencer3.1-H1-neo-negative-shRNA for 24 h, cells (3-
5 × 104 per well) were seeded into ECM gel pre-coated,
porous upper chamber inserts and allowed to invade
overnight at 37 °C in a CO2 incubator. Subsequently, the
insert was washed with PBS and the cells on the top sur-
face of the insert were removed by wiping with a cotton
swab. The cells that invaded the bottom surface of the
insert were fixed with methanol and stained by 0.5 %
crystal violet and then subjected to microscopic inspec-
tion. All fields were chosen and the numbers of pene-
trated cells were counted at 200× magnification. All data
were calculated based on triplicate experiments.
Histone/DNA fragment ELISA
Exponentially growing EC9706 and TE1 cells were plated
in sterile petri dishes and transfected with pSilencer3.1-H1-
neo-Bit1-shRNA or pSilencer3.1-H1-neo-negative -shRNA.
Cytosolic fractions of 5 × 104 cells per group served as an
antigen source in a sandwich ELISA using primary anti-
histone antibody-coated microplate and a secondary
peroxidase-conjugated anti-DNA antibody. The photomet-
ric immunoassay for histone-associated DNA fragments
was executed according to the manufacturer’s instructions
and absorbance (A) value was measured at 405 nm using a
Microplate Reader (BIO-TEK, Winooski, USA). A higher A
value was correlated with increased apoptosis. All data were
calculated based on triplicate experiments.
Immunoprecipitations (IP)
EC9706 cells were lysed for 30 min on ice with immuno-
precipitations (IP) buffer (Pierce, Rockford, IL). The ly-
sates were centrifuged at 12,000 g for 10 min at 4 °C.
The cell lysates (500 μg) was mixed with 5 μg of anti-
bodies against Bit1 or FAK, respectively. Subsequently,
immune complexes were collected with elution buffer at
3000 g centrifugation for 1 min at 4 °C according to
manufacturer’s protocol. Finally, the samples were sub-
mitted to immunoblotting assay.
In vivo experiment
All procedures were done according to protocols approved
by the Institutional Committee for Use and Care of Labora-
tory Animals of Zhengzhou University. Female BALB/c
nude mice (4–6 weeks old) were purchased from the
Beijing Weitong Lihua Experimental Animal Technical Co.,
Ltd. To observe the effect of Bit1 on tumor growth in vivo,
EC9706 cells (4 × 106) were subcutaneously implanted into
one flank in each of 20 nude mice. Once the tumor vol-
umes reached approximate 100 mm3 (length ×width2/2,
about on day 5), the mice were randomly divided into four
groups. The different complexes, which consisted of pSilen-
cer3.1-H1-neo-Bit1-shRNA (5 μg and 10 μg) or pSilen-
cer3.1-H1-neo-negative-shRNA (5 μg and 10 μg) and
corresponding volume of Lipofectamine 2000, were
injected to nude mice via intratumor route every 4 days (in-
jection on days 5, 9, 13, 17, respectively). The mice were
sacrificed on day 21, then the tumor tissues were harvested
and qRT-PCR, TUNEL and immunohistochemistry assays
were performed as described below.
Immunohistochemistry
Immunohistochemistry was performed on 4 mm thick
paraffin-embedded tissue sections as our previous descrip-
tion [19]. Briefly, the processed sections of Bit1 protein
were incubated with the same antibody as the Western
blotting, while Bcl-2 and MMP-2 protein were used anti-
Bcl-2 (1:2000) and anti-MMP-2(1:1000), respectively, and
PBS instead of Bit1, Bcl-2, and MMP-2 primary antibodies
was used as a negative control. The DAB Detection Kit
was used to develop staining signal according to the
protocols provided for the Ventana Molecular Discovery
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System (Illkirch, France). The slides were counterstained
with haematoxylin. All sections were investigated by light
microscopy. The staining evaluation was performed by
calculating the IOD (integrate optical density) using
the software of Biosens Digital Imaging System V1.6
(Shanghai, China) at 400× magnification. All of the
normal and neoplastic cells that both exhibited cyto-
plasmic immunoreactivity with clearly brown-yellow
were regarded as Bit1, Bcl-2, and MMP-2 positive
staining. A scoring system for Bit1, Bcl-2 and MMP-2
positive staining was carried out by the software
automatically.
In Situ Apoptosis Detection
Detection of apoptotic cells in tumor sections was per-
formed using the DeadEnd Colorimetric TUNEL System
(Promega) following the manufacturer’s instructions.
Briefly, sections were deparaffinized, rehydrated, and incu-
bated with proteinase K for 20 min at room temperature.
After washing with PBS, the sections were incubated with a
working concentration of recombinant Terminal Deoxynu-
cleotidyl Transferase (rTdT) at 37 °C for 1 h in wet and
dark atmosphere. The sections were washed with PBS and
immersed in 0.3 % hydrogen peroxide to block endogenous
peroxidase activity. The sections were subsequently washed
with PBS and incubated with the 50 μl streptavidin-HRP
working solution at 37 °C for 30 min. Finally, the resulting
dark brown signal was visualized with Diaminobenzidine
(DAB) as chromogen. Negative control (label solution con-
tained no terminal deoxynucleotidyl transferase in TUNEL
reaction mixture) and positive control (incubation of
permeabilized cells with 100 μl DNAse 1 buffer for 10 min
at 15-25 °C, prior to labeling procedures) were also per-
formed as internal controls.
RNA isolation and whole-genome gene expression profil-
ing of EC9706 cells
EC9706 cells were harvested 72 h after transfection with
pSilencer3.1-H1 -neo-Bit1-shRNA or pSilencer3.1-H1-
neo-negative-shRNA. Approximate 1 × 106 cells from
each sample were subjected to gene microarray assay.
Total RNA was extracted using TRIzol reagent (Invitrogen,
USA) following the manufacturer’s instructions and ana-
lyzed with Agilent SurePrint G3 Human GE 8 × 60 K
Microarray (Agilent technologies) by the Shanghai Biochip
Company (Shanghai, China). Data were annotated using
the SAS Analysis System and filtered by signal intensity and
detection call [present (P), marginal (M), or absent (A)].
Gene expression fold changes were compared between
Bit1-shRNA treated and negative-shRNA treated cells.




SPSS 17.0 statistical software package (SPSS, Inc., Chicago,
IL, USA) was used for statistical treatment. For the meas-
urement data, data were presented as mean ± SD. Differ-
ences among the groups were determined using one-way
ANOVA, and then multiple comparisons between groups
were performed using LSD t-test. For the count data, rank
sum test was used in the comparisons between groups. A
value of P less than 0.05 was considered as statistically
significant.
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